Safety and effectiveness of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: insights from the SPUM-ACS study.
Francesco BrunoFlorian A WenzlOvidio De FilippoSimon KralerFederico GiacobbeMarco RoffiOlivier MüllerLorenz RäberChristian TemplinGaetano Maria De FerrariFabrizio D'AscenzoThomas Felix LüscherPublished in: European heart journal. Cardiovascular pharmacotherapy (2024)
In patients with ACS undergoing PCI and receiving potent P2Y12 inhibitors, we observed a reduced risk of MACE and an increased risk of major bleedings at 1 year in patients treated with GPI. Although the routine use of GPI is currently not recommended, they might be considered in selected patients following a personalized balancing between ischaemic and bleeding risks.
Keyphrases
- acute coronary syndrome
- percutaneous coronary intervention
- end stage renal disease
- antiplatelet therapy
- ejection fraction
- newly diagnosed
- chronic kidney disease
- randomized controlled trial
- systematic review
- coronary artery disease
- acute myocardial infarction
- peritoneal dialysis
- prognostic factors
- heart failure
- patient reported outcomes
- st segment elevation myocardial infarction
- climate change
- left ventricular
- coronary artery bypass grafting